Drugs / 10E8VLS
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03565315 | Jul 2018 → Mar 2019 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 10E8VLS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03565315 ↗ |
| Known as | VRC-HIVMAB095-00-AB | “A Phase I Safety and Pharmacokinetics Study to Evaluate a Human Monoclonal Antibody (MAB) VRC-HIVMAB095-00-AB (10E8VLS) Administered Alone or Concurrently with MAB...” NCT03565315 ↗ |
| Modality | Monoclonal antibody | “10E8VLS is an investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.” NCT03565315 ↗ |